3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Onchocerciasis, Ocular: new trials by email Literature Review of Onchocerciasis, Ocular trials Research Report on Onchocerciasis, Ocular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis Ivermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole - Onchocercal Subcutaneous Nodule, Onchocerciasis | Phase 2 | Active not recruiting | Washington University School of Medicine | 300 | 2024-04-05 | 2025-12-18 |
| Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients Moxidectin 2 MG Oral Tablet, Ivermectin 3Mg Tab, Placebo oral tablet - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Center for Research on Filariasis and Other Tropical Diseases, Cameroon | 72 | 2022-04-07 | 2025-02-24 |
| Emodepside Phase II Trial for Treatment of Onchocerciasis emodepside, matching placebo of emodepside, ivermectin - Onchocerciasis | Phase 2 | Unknown | Drugs for Neglected Diseases | 578 | 2021-08-30 | 2024-03-05 |
| Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection ABBV-4083, Placebo for ABBV-4083, Albendazole - Onchocerciasis | Phase 2 | Terminated | AbbVie | 153 | 2021-05-22 | 2024-09-19 |
| Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients LEV 1 mg/kg, LEV 1,5 mg/kg, LEV 2,5 mg/kg - Onchocerciasis, Ocular, Loiasis | Phase 2 | Completed | Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 255 | 2021-01-16 | 2021-09-20 |
| Pediatric Pharmacokinetics And Safety Study Of Moxidectin moxidectin - Onchocerciasis | Phase 2 | Withdrawn | Pfizer | 2011-04-01 | 2012-03-29 | |
| Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection 2 mg moxidectin, ivermectin 150 mcg/kg, 4 mg moxidectin - Onchocerciasis | Phase 2 | Completed | Medicines Development for Global Health | 172 | 2006-09-06 | 2022-12-15 |
Onchocerciasis (5) · Loiasis (2) · Filariasis (1) · Helminthiasis (1) · Neglected Diseases (1) · Nematode Infections (1) · Parasitic Diseases (1) · Skin Diseases (1) · Skin Diseases, Infectious (1) · Skin Diseases, Parasitic (1)
Eye Diseases (7) · Eye Infections (7) · Eye Infections, Parasitic (7) · Infections (7) · Secernentea Infections (7) · Spirurida Infections (7) · Vector Borne Diseases (7) · Filariasis (6) · Helminthiasis (6) · Nematode Infections (6) · Parasitic Diseases (6) · Skin and Connective Tissue Diseases (5) · Skin Diseases (4) · Skin Diseases, Infectious (4) · Skin Diseases, Parasitic (4)
Ivermectin (4) · moxidectin (4) · Albendazole (2) · Bay 44-4400 (1) · Diethylcarbamazine (1) · Levamisole (1) · Tablets (1) · emodepside (1)
AbbVie (1) · Center for Research on Filariasis and Other Tropical Diseases, Cameroon (1) · Drugs for Neglected Diseases (1) · Medicines Development for Global Health (1) · Pfizer (1) · Programme National de Lutte contre l'Onchocercose, Republic of the Congo (1) · Washington University School of Medicine (1)
Democratic Republic of the Congo (2) · Ghana (2) · Cameroon (1) · Liberia (1) · Republic of the Congo (1)
Gary Weil, MD (1) · Nicholas Opoku, MD (1) · Patrick Kpanyen, PhD (1) · Peter Fischer, PhD (1)